Oberweis Asset Management Inc Ligand Pharmaceuticals Inc Transaction History

Oberweis Asset Management Inc

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2019 Feb 14, 2020	SELL	$96.94 - $113.59 $236,533 - $277,159	-2,440 Closed	0 $0
Q3 2019 Nov 14, 2019	SELL	$86.25 - $120.16 $112,125 - $156,208	-1,300 Reduced 34.76%	2,440 $243,000
Q2 2019 Aug 14, 2019	SELL	$107.38 - $129.34 $4.39 Million - $5.29 Million	-40,909 Reduced 91.62%	3,740 $427,000
Q1 2019 May 15, 2019	BUY	$105.93 - $142.47 $150,420 - $202,307	1,420 Added 3.28%	44,649 $5.61 Million
Q4 2018 Feb 14, 2019	BUY	$128.36 - $272.13 $980,927 - $2.08 Million	7,642 Added 21.47%	43,229 $5.87 Million
Q3 2018 Nov 14, 2018	SELL	$211.18 - $274.49 $2.86 Million - $3.72 Million	-13,540 Reduced 27.56%	35,587 $9.77 Million
Q2 2018 Aug 14, 2018	BUY	$150.77 - $207.98 $50,507 - $69,673	335 Added 0.69%	49,127 $10.2 Million
Q1 2018 May 15, 2018	SELL	$138.63 - $182.62 $1.46 Million - $1.93 Million	-10,560 Reduced 17.79%	48,792 $8.06 Million
Q4 2017 Feb 14, 2018	BUY	$128.36 - $147.04 $1.01 Million - $1.15 Million	7,850 Added 15.24%	59,352 $8.13 Million
Q3 2017 Nov 13, 2017	BUY	$120.91 - $137.94 $6.23 Million - $7.1 Million	51,502	51,502 $7.01 Million

257

18.2M

26.8K

9.3K

Ticker LGND
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 16,882,800
Market Cap $2.07B
Description
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Veklury for the treatment of moderate or severe COVID-19;...

Get notified when there are updates to the investment portfolio of Oberweis Asset Management Inc, based on Form 13F filings with the SEC.

Stay updated on Oberweis Asset Management Inc with notifications on news.